ArticleTranslational vision science & technology2025
Near-Real Surgical Specimens (NRSS): A Novel Platform for Standardized Assessment of Suprachoroidal Drug Delivery.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mitochondrial Transplantation in the Eye: A Review and Evaluation of Surgical Approaches.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Suprachoroidal (SC) drug delivery is a promising avenue for treating posterior segment ocular diseases. Current ex vivo models, primarily human cadaveric eyes, are limited by tissue variability and altered post-mortem fluid dynamics. We introduce near-real surgical specimens (NRSS), an engineered ocular tissue platform, to overcome these limitations and provide standardized, reproducible evaluation of SC drug delivery. Methods: NRSS ocular models were engineered with biomimetic properties calibrated to fresh human tissue. Suprachoroidal injections of a contrast-enhanced balanced salt solution (100 µL) were performed in NRSS specimens (n = 8) using the Everads Suprachoroidal Injector, which features a 30-gauge needle and a non-sharp nitinol tissue separator for tangential blunt dissection into the suprachoroidal space (SCS). An integrated contrast imaging system enabled real-time visualization. Key parameters, including SC coverage patterns, interspecimen variability (coefficient of variation [CV]), and injection dynamics, were quantified and compared to published human cadaveric eye data. Results: The NRSS platform demonstrated consistent SC coverage patterns. With the Everads Suprachoroidal Injector, injectate exhibited an initial posterior diffusion from the injection site, followed by postero-circumferential spread. NRSS specimens showed significantly reduced inter-specimen variability in SC coverage compared to reported cadaveric studies (CV: 6.8% for NRSS vs. 17.7% for cadaveric tissue; P < 0.01). Real-time visualization provided detailed insights into the dynamic characteristics of SC injection, including fluid flow patterns and tissue interactions not readily observable in static cadaveric models. Conclusions: The NRSS platform offers a reproducible and standardized method for evaluating SC drug delivery, closely mimicking clinically relevant biomechanical properties. It enables direct visualization of injection dynamics and holds potential for customization to model pathologic conditions, providing distinct advantages over traditional cadaveric models for device testing, therapeutic assessment, and surgical training. The Everads Suprachoroidal Injector demonstrated effective and reliable access to the SCS in NRSS models with a characteristic posterior-first spread pattern. Translational Relevance: NRSS technology addresses critical limitations in current SC injection assessment models. It provides a robust, standardized platform for optimizing delivery devices, quantitatively evaluating novel therapeutics, and enhancing surgical training for SC procedures, thereby potentially accelerating the clinical translation of SC therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.